The Efficacy and Safety of Combination Glycoprotein Iibiiia Inhibitors And
Total Page:16
File Type:pdf, Size:1020Kb
Interventional Cardiology The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy–facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: A meta-analysis of randomized clinical trials Mohamad C.N. Sinno, MD, Sanjaya Khanal, MD, FACC, Mouaz H. Al-Mallah, MD, Muhammad Arida, MD, and W. Douglas Weaver, MD Detroit, MI Objective We reviewed the literature and performed a meta-analysis comparing the safety and efficacy of adjunctive use of reduced-dose thrombolytics and glycoprotein (Gp) IIbIIIa inhibitors to the sole use of Gp IIbIIIa inhibitors before percutaneous coronary intervention (PCI) in patients presenting with acute ST-segment elevation myocardial infarction (STEMI). Background Early reperfusion in STEMI is associated with improved outcomes. The use of reduced-dose thrombolytic and Gp IIbIIIa inhibitors combination before PCI in the setting of acute STEMI remains controversial. Methods We performed a literature search and identified randomized trials comparing the use of combination therapy–facilitated PCI versus PCI done with Gp IIbIIIa inhibitor alone. Included studies were reviewed to determine Thrombolysis in Myocardial Infarction (TIMI)-3 flow at baseline, major bleeding, 30-day mortality, TIMI-3 flow after PCI,and 30-day reinfarction. We performed a random-effect model meta-analysis. We quantified heterogeneity between studies with I2. A value N50% represents substantial heterogeneity. Results We identified 4 clinical trials randomizing 725 patients; 424 patients were pretreated with combination therapy before PCI, and 301 patients had Gp IIbIIIa inhibitor alone during PCI. Combination therapy–facilitated PCI was associated with a 2-fold increase in TIMI-3 flow upon arrival to the catheterization laboratory compared with the sole use of upstream Gp IIbIIIa inhibitors (192/390 patients [49%] versus 60/284 [21%]; relative risk [RR], 2.2; P b .00001). However, post-PCI TIMI-3 flow was similar between the 2 groups (279/319 patients [87%] versus 188/212 [88%]; RR, 0.99; P = .85). Major bleeding events significantly increased in the combination therapy group (40/420 patients [9.5%] versus 14/299 [4.7%]; RR, 2.2; P = .007). The 30-day mortality (15/424 patients [3.5%] versus 5/301 [1.7%]; RR, 1.47; P = .46) and 30-day reinfarction rate (5/424 patients [1.1%] versus 3/301 [1.0%]; RR, 0.96; P = .96) were similar in the 2 treatment groups. Conclusions Awaiting the results of the ongoing clinical trials, the current cumulative evidence does not support the routine use of combination of reduced-dose thrombolytic and Gp IIbIIIa inhibitor therapy–facilitated PCI for the treatment of STEMI. (Am Heart J 2007;153:579286.) The primary goal of therapy for acute ST-segment artery (IRA) blood flow. Irrespective of whether a elevation myocardial infarction (STEMI) is early, rapid, mechanical versus pharmacological strategy is used, complete, and sustained restoration of infarct-related Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow in the culprit artery within 90 minutes of presentation has been shown to correlate with im- From the Henry Ford Health System, Detroit, MI. proved 30-day1 and long-term2 survival in patients with Submitted June 20, 2006; accepted December 26, 2006. Reprint requests: Sanjaya Khanal, MD, FACC, Heart Center of Antelope Valley, 43807 acute STEMI. North 10th Street West, Lancaster, CA 93536. Primary percutaneous coronary intervention (PCI) is E-mail: [email protected] currently the preferred approach to reperfusion therapy 0002-8703/$ - see front matter n 2007, Published by Mosby, Inc. when delivered expeditiously in centers with docu- 3 doi:10.1016/j.ahj.2006.12.024 mented expertise and outcomes. Time to treatment, American Heart Journal 580 Sinno et al April 2007 Table I. Summary of characteristics in trials comparing simultaneous use of thrombolytics and glycoprotein IIb/IIIa inhibitors vs glycoprotein IIb/IIIa Inhibitors alone for PCI No. of females/ Symptom onset No. of Patients Total (%) Mean Age yrs. to drug, mins. Combination IIb/IIIa Combination IIb/IIIa Combination IIb/IIIa Combination IIb/IIIa Inclusion therapy inhibitors therapy inhibitors therapy inhibitors therapy inhibitors Study Criteria group group group group group group group group ADVANCE-MI STEMI b6hrs. 74 74 24/148 (16) 28/148 (19) 58 55 - - SPEED STEMI b12hrs. 191 63 49/254 (19) 21/254 (8) 59 57 153 138 BRAVE STEMI b12hrs. 125 128 28/253 (11) 33/253 (13) 63.1 62.3 160 164 APAMIT STEMI b6hrs. 34 36 8/70 (11) 6/70 (9) 55 56 205 259 however, remains an important determinant of clinical PCI, the range of initial pharmacotherapy encompasses outcome in patients with acute STEMI. thrombolytic and glycoprotein (Gp) IIbIIIa inhibitors. Despite the better outcomes, primary PCI has not The use of Gp IIbIIIa inhibitors has been shown to become the treatment of choice for most patients with improve short-term outcomes in most studies of primary STEMI because of logistical issues and the limited PCI.8,9 However, full-dose fibrinolysis-facilitated PCI has availability of institutions that can offer this treatment recently been shown to result in worse outcome than modality in a timely and efficient manner. In the current primary PCI alone.10 The results with combination of US practice, only 4.2% of transferred patients with acute reduced-dose thrombolytic and Gp IIbIIIa inhibitors STEMI were treated within 90 minutes in the National before PCI in patients with MI are however not clear. A Registry of Myocardial Infarction 3/4 registry.4 The idea recent meta-analysis comparing primary and multiple of prehospital ambulance triage of patients with STEMI regimens of thrombolytic-facilitated PCI for STEMI to PCI hospitals has been suggested to decrease inherent showed a higher TIMI grade 3 flow on initial angiogra- time delay that ensues when these patients are seen in phy, but this translated into higher major bleeding non-PCI hospitals. Nallamothu et al5 obtained PCI status events, increased mortality, nonfatal reinfarction, urgent of hospitals from the American Hospital Association target revascularization, and stroke11 compared with annual survey and established the location of the primary PCI alone. This study, however, does not population from the 2000 US census and found that 79% provide guidance about the common practice of the use of the adult population lived within 60 minutes of a PCI of reduced-dose fibrinolytic and Gp IIbIIIa inhibitors hospital. Among those with non-PCI hospitals as the before PCI in patients with acute STEMI. We performed closest facility, the additional time to arrive to a PCI a meta-analysis of randomized clinical trials12-15 testing hospital was 30 minutes.5,6 However, with the variability the safety and efficacy of combination therapy (reduced- of the emergency medical system in the United States, dose thrombolytic + Gp IIbIIIa inhibitors)–facilitated PCI getting electrocardiograms in the ambulance for patients versus PCI performed only with Gp IIbIIIa inhibitors. with chest pain and training paramedics to interpret these electrocardiograms is the major issue. Pharmaco- Methods logical therapy, however, can be carried out expedi- tiously and without site-specific variations in outcome in Study objectives and design patients with STEMI.7 Therefore, it is logical to think that Our primary aim was to compare simultaneous administra- tion of Gp IIbIIIa inhibitors and reduced-dose fibrinolytics initial early pharmacological therapy followed by PCI before PCI to primary PCI done with Gp IIbIIIa inhibitors in may deliver both expediency and efficacy that is desired patients with STEMI. ST-segment elevation myocardial infarc- in treating myocardial infarction (MI) patients. tion was defined according to the inclusion criteria of the In fact, many institutions have current policies of trials concerned. providing initial primary PCI alone, thrombolytic thera- py alone, or combination therapy followed by PCI based Search strategy on estimated time to treatment. In addition to standard All randomized, controlled trials comparing facilitated PCI to therapy of aspirin, heparin, clopidogrel during primary primary angioplasty were identified using a 2-level search American Heart Journal Sinno et al 581 Volume 153, Number 4 trials were also excluded. Outcome data had to be available on culprit artery patency evaluated on admission by TIMI flow grades, bleeding, and mortality. Two authors (M.S., M.M.) independently reviewed abstracts or complete articles. Only Combined 4 nonoverlapping studies met the inclusion criteria. Two Clinical End reviewers performed independent data extraction; all discrep- Trial Angiographic Point (Time to ancies were identified and resolved by consensus or, as Agents eight % End Points Follow up) needed, with a third investigator and confirmed by consensus. Tenecteplase, 20 TIMI 3 Death, Reinfarction Eptifibatide flow grade or new CHF End points and definitions @ 30 days Reteplase, 35 TIMI 3 Death, Reinfarction The primary angiographic end point was TIMI flow grade 3 Abciximab flow grade or urgent on the first angiogram, which defined open culprit artery on Revascularization admission. The TIMI grade 3 flow was also assessed after PCI. @ 30 days Reteplase, 35 TIMI 3 Infarct size by SPECT, The clinical end points were all-cause mortality, reinfarction Abciximab flow grade Death, Reinfarction, rate, and major bleeding events at 30 days follow-up. major Bleeding, and hemorrhagic Stroke Alteplase, 10 TIMI 3 ACE= Death,